Q&A session on the general overview of lung cancer
12 November 2009
Presented by Dr Sanjay Popat, Senior Lecturer & Honorary Consultant in Medical Oncology.
Dr Sanjay Popat
Dr Popat is a clinical senior lecturer at the National Heart and Lung Institute and honorary consultant thoracic medical oncologist at The Royal Marsden. He qualified in 1994 and completed medical oncology training at The Royal Marsden. Dr Popat has published in the fields of genetics, therapeutic biomarkers and medical oncology.
- Related Drug Categories
- Adjuncts
- Antineoplastics
- Related MIMS Guidelines and Summaries
- Eribulin for the Treatment of Locally Advanced or Metastatic Breast Cancer
- Cetuximab, Bevacizumab and Panitumumab for the Treatment of Metastatic Colorectal Cancer After First-Line Chemotherapy
- Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia (CML), and Dasatinib and Nilotinib for People with CML for Whom Treatment with Imatinib has Failed because of Intolerance
Additional Information
Latest jobs Jobs web feed
- Salaried GP The Practice plc £75-85k FTE +NHS pension, Ely or Leicester
- Regional Clinical Leads The Practice plc Salary £95-105k FTE + NHS pension, Leicester or Sheffield
- Salaried/Lead GPs Malling Health Competitive, role dependant, NHS Pension and defence fees reimbursed, Nationwide
- Newly qualified GP's dr-locums £70 an hour plus, Nationwide
- Full Time Partner (9 sessions) Charnwood Community Medical Group Equal share partner, Loughborough, LEICS
- Locum GP Meddoc Locums £600-£800 A day, London & Essex
Most read
- Health secretary says GPs have 'ethical duty' to save NHS costs
- GPs face 'outcomes targets overload', patient group warns
- LMCs Conference 2012 - Live Blog
- QOF errors trigger £1,000 top ups and clawbacks
- Women to be screened later for cervical cancer in Scotland and Wales
- LMCs conference 2012 - Full coverage
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
